Results 111 to 120 of about 46,872 (214)

Repurposing SGLT2 inhibitors [PDF]

Nature Reviews Drug Discovery, 2018
openaire   +1 more source

SGLT2 inhibitors and bone health in CKD. [PDF]

Clin Kidney J
Haarhaus M.
europepmc   +1 more source

Application of SGLT2 inhibitors in kidney diseases: a bibliometric analysis. [PDF]

Front Med (Lausanne)
Hu Q, Jin H, Li X, Hu L.
europepmc   +1 more source

SGLT2 Inhibitors and Liver Cirrhosis: Hype or Hope? [PDF]

Life (Basel)
Brusnic O, Onisor DM, Boicean A, Porr C, Sofonea FD, Anderco P, Ichim C.   +6 more
europepmc   +1 more source

Beyond safety: adverse events and unanticipated advantages of SGLT2 inhibitors. [PDF]

Eur J Clin Pharmacol
Falsetti L, Tarquinio N, Mucci L, Santini S, Guerrieri E, Giovenali L, Pierdomenico G, Zaccone V, Viticchi G, Moroncini G.   +9 more
europepmc   +1 more source

Next-Generation SGLT2 Inhibitors: Innovations and Clinical Perspectives. [PDF]

Biomedicines
Movila D, Seiman DD, Dragan SR.
europepmc   +1 more source

Another pleiotropic effect of SGLT2 inhibitors: Is it a new frontier in thyroid function regulation? [PDF]

Thyroid Res
Szklarz M, Wołos-Kłosowicz K, Szulc J, Górny J, Modzelewski R, Matuszewski W.   +5 more
europepmc   +1 more source

Urea cycle modulation by combined SGLT2 inhibitors and metformin. [PDF]

BMC Med
Harada M, Adam J, Han S, Shi M, Ge J, Lintelmann J, Cecil A, Zukunft S, Prehn C, Witting M, Scheerer MF, Neschen S, Irmler M, Beckers J, Adamski J, Teupser D, Linkohr B, Gieger C, de Angelis MH, Peters A, Wang-Sattler R.   +20 more
europepmc   +1 more source

SGLT2 inhibitors in cardiac amyloidosis: mechanistic insights and clinical perspectives-a narrative review. [PDF]

Cardiovasc Diabetol Endocrinol Rep
Özlek B, Tanik VO.
europepmc   +1 more source

Repurposing SGLT2 Inhibitors for Cirrhotic Ascites: From Mechanistic Research to Clinical Exploration. [PDF]

J Clin Transl Hepatol
Gao Y, Gao Y, Ji D, Hu Z.
europepmc   +1 more source